Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Boundless Bio Inc. (BOLD)
NASDAQ:BOLD
RESEARCH TOOLSreports
Boundless Bio Inc. (BOLD) Stock Price & Analysis
9 Followers
BOLD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$8.25 - $15.24
Previous Close$9.62
Volume41.91K
Average Volume (3M)169.90K
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)$120.75M
Total Debt (Recent Filing)$2.19M
Price to Earnings (P/E)―
Beta4.36
Next Earnings
May 13, 2024EPS Estimate
-$0.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding22,254,537
10 Day Avg. Volume75,645
30 Day Avg. Volume169,899
Standard Deviation0.16
R-Squared1.00
Alpha-0.20
Financial Highlights & Ratios
Price to Book (P/B)2.15
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-5.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$23.00Price Target Upside139.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Boundless Bio Inc. News
PremiumCompany Announcements
Boundless Bio Inc. Shifts Corporate Updates to IR Website
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsACR-368 demonstrates 50% ORR in patients enriched with OncoSignature test, indicating clear activity in a targeted patient population and potential for accelerated approval.
Innovation And TechnologyBOLD is developing a diagnostic to detect ecDNA and has a platform called Spyglass for discovering ecDNA interventions, positioning the company at the forefront of targeted oncology.
Product PipelineBOLD continues to enroll patients in the POTENTIATE trial for BBI-355, BOLD's lead asset, showcasing the company's progress in its clinical program.
Bears Say
Clinical Trial ConcernsPatients not enriched with OncoSignature did not respond to ACR-368, suggesting the necessity of patient selection for effective treatment.
Lack Of TransparencyThe company did not provide much detail into the OncoSignature diagnostic, limiting direct comparisons to other diagnostics.
Scientific UncertaintyWhile BOLD's focus on extra-chromosomal DNA is groundbreaking, the biological role of ecDNA is not fully understood, introducing inherent risks to their novel therapeutic approaches.
---
Ownership Overview
22.70% Insiders
0.00% Mutual Funds
35.59% Other Institutional Investors
41.72% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
BOLD FAQ
What was Boundless Bio Inc.’s price range in the past 12 months?
Boundless Bio Inc. lowest stock price was $8.25 and its highest was $15.24 in the past 12 months.
What is Boundless Bio Inc.’s market cap?
Currently, no data Available
When is Boundless Bio Inc.’s upcoming earnings report date?
Boundless Bio Inc.’s upcoming earnings report date is May 13, 2024 which is 27 days ago.
How were Boundless Bio Inc.’s earnings last quarter?
Currently, no data Available
Is Boundless Bio Inc. overvalued?
According to Wall Street analysts Boundless Bio Inc.’s price is currently Undervalued.
Does Boundless Bio Inc. pay dividends?
Boundless Bio Inc. does not currently pay dividends.
What is Boundless Bio Inc.’s EPS estimate?
Boundless Bio Inc.’s EPS estimate is -$0.64.
How many shares outstanding does Boundless Bio Inc. have?
Boundless Bio Inc. has 22,254,538 shares outstanding.
What happened to Boundless Bio Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Boundless Bio Inc.?
Among the largest hedge funds holding Boundless Bio Inc.’s share is RA Capital Management. It holds Boundless Bio Inc.’s shares valued at 31M.
---
Boundless Bio Inc. Stock Smart Score
Company Description
Boundless Bio Inc.
Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California.
---
BOLD Stock 12 Month Forecast
Average Price Target
$23.00
▲(139.09% Upside)
Technical Analysis
Best Analysts Covering BOLD
1 Year
1 Year Success Rate
0/2 ratings generated profit
1 Year Average Return
-6.90%
reiterated a buy rating 27 days ago
Copying Andrew Berens's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -6.90% per trade.
---